RBRunfa Bao

Runfa Bao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Runfa Bao has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Chengkai Jiang

    Department of Biliary-Pancreatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China

    1 shared publication
  • Fusheng E

    Department of General Surgery, Shigatse People's Hospital Shigatse China

    1 shared publication
  • Honggang Xiang

    Department of General Surgery Pudong New Area People's Hospital Shanghai China

    1 shared publication
  • Jia-Wei Mei

    Department of General Surgery, Xinhua Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai, China

    1 shared publication
  • Jun Gu

    Department of General Surgery and Laboratory of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, People’s Republic of China

    1 shared publication
  • Liguo Liu

    Department of Biliary-Pancreatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China

    1 shared publication

Latest Publications

  • Open Access

    Machine Learning–Driven Prognostic Model Integrating Lymphocyte‐to‐C‐Reactive Protein Ratio and TNM Staging in Gallbladder Cancer

    by Mingyang Wang, Zhengyu Chen, Fusheng E, Jun Gu, Runfa Bao

    Background: A comprehensive preoperative assessment of the patient's physical condition is crucial for predicting the prognosis of patients undergoing radical cholecystectomy for gallbladder cancer (GBC). This study aimed to develop a prognostic model integrating preoperative hematological parameters and clinical information to predict postoperative survival in patients with GBC. Methods: Patients who underwent radical cholecystectomy for GBC between 2000 and 2024 at Xinhua Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, and Shigatse People's Hospital were included in this study. Data on demographic features, clinical parameters, laboratory results, and clinical outcomes were collected. Univariate and multivariate Cox regression analyses, time‐dependent ROC curve analysis, and the least absolute shrinkage and selection operator (LASSO) regression were used to identify the key factors for model development. Various machine learning models were constructed based on these findings. Internal validation assessed model stability, while clinical decision analysis evaluated its practical utility. Results: A total of 184 patients were included, with a mean age of 67 years. Key predictors identified through univariate and multivariate Cox regression, time‐dependent ROC, and LASSO analyses were the lymphocyte‐to‐C‐reactive protein ratio (LCR) and tumor‐node‐metastasis (TNM) staging. The best‐performing model was logistic regression, with the following area under the curve (AUC) values: for the training set, 0.785 at 1 year, 0.853 at 2 years, and 0.873 at 3 years; and for the test set, 0.800 at 1 year, 0.870 at 2 years, and 0.872 at 3 years. Clinical decision analysis confirmed the model's clinical applicability. Conclusion: The machine learning model incorporating LCR and TNM staging is a robust tool for predicting postoperative survival following radical resection for GBC.


  • Open Access

    Rac GTPase activating protein 1 promotes gallbladder cancer via binding DNA ligase 3 to reduce apoptosis

    by Rui Bian, Wei Dang, Xiaoling Song, Liguo Liu, Chengkai Jiang, Yang Yang, Yongsheng Li, Lin Li, Xuechuan Li, Yunping Hu, et al.

    Rac GTPase activating protein 1 (RACGAP1) has been characterized in the pathogenesis and progression of several malignancies, however, little is known regarding its role in the development of gallbladder cancer (GBC). This investigation seeks to describe the role of RACGAP1 and its associated molecular mechanisms in GBC. It was found that RACGAP1 was highly expressed in human GBC tissues, which was associated to poorer overall survival (OS). Gene knockdown of RACGAP1 hindered tumor cell proliferation and survival both in vitro and in vivo. We further identified that RACGAP1 was involved in DNA repair through its binding with DNA ligase 3 (LIG3), a crucial component of the alternative-non-homologous end joining (Alt-NHEJ) pathway. RACGAP1 regulated LIG3 expression independent of RhoA activity. RACGAP1 knockdown resulted in LIG3-dependent repair dysfunction, accumulated DNA damage and Poly(ADP-ribosyl) modification (PARylation) enhancement, leading to increased apoptosis and suppressed cell growth. We conclude that RACGAP1 exerts a tumor-promoting role via binding LIG3 to reduce apoptosis and facilitate cell growth in GBC, pointing to RACGAP1 as a potential therapeutic target for GBC.


  • Open Access

    MicroRNA-1275 inhibits cell migration and invasion in gastric cancer by regulating vimentin and E-cadherin via JAZF1

    by Jia-Wei Mei, Zi-Yi Yang, Hong-Gang Xiang, Runfa Bao, Yuan-Yuan Ye, Tai Ren, Xue-Feng Wang, Yi-Jun Shu

    Emerging evidence has shown that miR-1275 plays a critical role in tumour metastasis and the progression of various types of cancer. In this study, we analysed the role and mechanism of miR-1275 in the progression and prognosis of gastric cancer (GC). Target genes of miR-1275 were identified and verified by luciferase assay and Western blotting. The function of miR-1275 in invasion and metastasis was analysed in vitro and in vivo in nude mice. The signal pathway regulated by miR-1275 was examined by qRT-PCR, Western blotting and chromatin immunoprecipitation analyses. The expression of miR-1275and JAZF1 were measured in specimens of GC and adjacent non cancerous tissues. We identified JAZF1 as a direct miR-1275 target. miR-1275 supresses migration and invasion of GC cells in vitro and in vivo, which was restored by JAZF1 overexpression. Moreover, JAZF1 was recognized as a direct regulator of Vimentin. Knocking-down miR-1275 or overexpressing JAZF1 resulted in upregulation of Vimentin but downregulation of E-cadherin. Meanwhile, we validated in 120 GC patients specimens that low miR-1275expression and high JAZF1 mRNA expression levels were closely associated with lymph node metastasis and poor prognosis. The expression of JAZF1 in protein level displayed the correlations with Vimentin but inversely with E-cadherin. Increased miR-1275 expression inhibited GC metastasis by regulating vimentin/E-cadherin via direct suppression of JAZF1expression, suggesting that miR-1275 is a tumour-suppressor miRNA with the potential as a prognostic biomarker or therapeutic target in GC.